benign%20prostatic%20hyperplasia
BENIGN PROSTATIC HYPERPLASIA
Treatment Guideline Chart
Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
The exact cause of BPH is still not well understood.

Benign%20prostatic%20hyperplasia Management

Follow Up

  • Patients on watchful waiting should be assessed at 6 months and then annually, provided that there are no absolute indications for surgery and symptoms do not deteriorate
  • Patients on pharmacological therapy should be assessed 4-12 weeks after initiating treatment to determine response to treatment and safety
    • Patients taking alpha blockers, anticholinergics, beta-3 adrenergic agonist, PDE5 inhibitors or combination therapy should be assessed at 4-6 weeks after drug initiation and then every 6-12 months thereafter
    • Patients taking 5-alpha reductase inhibitors should be assessed at 3-6 months after drug initiation and then every 6-12 months thereafter
      • Patients on 5-alpha reductase inhibitors should be monitored with annual DRE and PSA
  • Patients who underwent surgical therapy should be assessed 4-6 weeks after catheter removal to evaluate for treatment response and adverse events
    • No further reassessment is necessary in patients without adverse events and with symptomatic relief
Editor's Recommendations
Special Reports